Clinical Trial Update: Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a Dexmedetomidine Transdermal System (DMTS) for agitation in Alzheimer's-type dementia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Dexmedetomidine Transdermal System (DMTS) (dexmedetomidine)

Snippet

Sponsor: Teikoku Pharma USA, Inc. | Conditions: Agitation | Phase 2 | Status: RECRUITING